Welcome to LookChem.com Sign In|Join Free
  • or

864070-44-0

Post Buying Request

864070-44-0 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
Empagliflozin
Cas No: 864070-44-0
USD $ 5.0-5.0 / Metric Ton No Data 10 Kilogram/Month Beijing Mesochem Technology Co.,LTD Contact Supplier
Good Price Purity 99.9%, Empagliflozin Powder
Cas No: 864070-44-0
USD $ 300.0-500.0 / Gram 1 Gram 50 Kilogram/Month Beijing Yibai Biotechnology Co., Ltd Contact Supplier
Good Price Purity 99.9%, Empagliflozin Powder CAS NO.864070-44-0
Cas No: 864070-44-0
No Data 1 Metric Ton 1 Metric Ton/Day Zibo dorne chemical technology co. LTD Contact Supplier
Empagliflozin
Cas No: 864070-44-0
No Data 1 Gram 500 Kilogram/Year Raspberry Inter (jiangsu) Co., Ltd. Contact Supplier
Empagliflozin CAS864070-44-0
Cas No: 864070-44-0
No Data 1 Gram 500 Kilogram/Year Hangzhou Hysen Pharma co.,Ltd. Contact Supplier
Empagliflozin
Cas No: 864070-44-0
No Data 1 Kilogram 500 Kilogram/Month Huarong Industrial Group Ltd. Contact Supplier
Empagliflozin
Cas No: 864070-44-0
No Data No Data No Data Koning Pharmchem Co., Ltd. Contact Supplier
empagliflozin
Cas No: 864070-44-0
USD $ 2600.0-3000.0 / Gram 100 Gram 10 Metric Ton/Month Hebei yanxi chemical co.,LTD. Contact Supplier
High quality 864070-44-0 empagliflozin
Cas No: 864070-44-0
USD $ 1300.0-1600.0 / Kilogram 1 Kilogram 99999 Kilogram/Year Hangzhou Dingyan Chem Co., Ltd Contact Supplier
High quality Empagliflozin Cas 864070-44-0 with factory price
Cas No: 864070-44-0
USD $ 2500.0-2727.0 / Kilogram 1 Kilogram 100 Kilogram/Month Wuhan Fortuna Chemical Co.,Ltd Contact Supplier

864070-44-0 Usage

Uses

Empagliflozin is a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.

Clinical research

FDA approval of empagliflozin(Jardiance) was based on the results of seven clinical trials conducted in nearly 4,500 patients with type 2 diabetes mellitus. Compared to the placebo group, all patients taking empagliflozin(Jardiance) had a significantly lower HbA1c level. The most common adverse reactions are urinary tract infections and female reproductive system infections.
On March 21, 2014, European Medicines Agency (EMA) Commission on Human Medicines recommended the approval of the sodium glucose co-transporter-2 (SGLT2) inhibitor (empagliflozin) for the treatment of adult type 2 diabetes mellitus.
On May 23, 2014, European Medicines Agency (EMA) approved for empagliflozin’s listing in Europe.
On June 16, 2014, the Boehringer-Erya Diabetes Federation released the latest data of empagliflozin Phase II clinical trials at the 74th American Diabetes Association Science Conference (ADA2014). In a two-year study, empagliflozin or glimepiride was used in the treatment of adult patients with type 2 diabetes based on metformin. The results showed that empagliflozin(Jardiance) reduced HbA1c more significantly compared with glimepiride, while the effect of weight and blood pressure treatment are equivalent with glimepiride. Another 52-week study was conducted in patients with type 2 diabetes who were still unable to adequately control blood glucose levels with high doses of insulin (with or without metformin). The results showed that compared with placebo, Jardiance significantly reduced blood glucose levels and weight, and reduced the dose of insulin, with Jardiance or placebo on a daily basis with multiple injections of insulin. In both studies, the safety of empagliflozin was consistent with previous studies.
FDA-related reports write that the drug should not be used in the following types of patients: type 1 diabetes, elevated blood or urine ketones (diabetic ketoacidosis), severe kidney damage, end-stage renal disease or dialysis patients. The most common side effects are urinary tract infections and female genital infections.
Empagliflozin can cause dehydration and lead to decreased blood pressure, resulting in patients with dizziness or fainting and decreased renal function. The risk of older patients, especially those with impaired renal function and diuretics, appears to be greater.
FDA requires Boehring and Eli Lilly to conduct four post-marketing studies: complete ongoing cardiovascular outcome trials, pediatric pharmacokinetics and pharmacodynamics trials, pediatric safety and efficacy trials, toxicity test for the drug (especially effect for renal function, bone and growth and development)

Definition

ChEBI: A C-glycosyl compound consisting of a beta-glucosyl residue having a (4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl group at the anomeric centre. A sodium-glucose co-transporter 2 inhibitor u ed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Precautions

Do NOT use empagliflozin if:
  • you are allergic to any ingredient in empagliflozin
  • you have type 1 diabetes
  • you have high blood or urine ketone levels (diabetic ketoacidosis)
  • you have severe kidney problems or are on dialysis

References

https://en.wikipedia.org/wiki/Empagliflozin
https://www.drugs.com/cdi/empagliflozin.html

Description

Empagliflozin(trade name Jardiance) is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and causes sugar in the blood to be excreted by the kidneys and eliminated in urine. On August 1, 2014, the Food and Drug Administration (FDA) officially approved the drug for the treatment of type 2 diabetes, to improve and control blood glucose of adults. Empagliflozin is the third SGLT-2 inhibiting drugs approved by FDA. Another two SGLT-2 inhibitor drugs, canagliflozin and dapagliflozin, belonging to Johnson Pharmaceuticals, AstraZeneca and Bristol-Myers Squibb respectively, are approved by FDA in November 2013 and January 2014 respectively. The new drug Empagliflozin’s application to FDA can be described as twists and turns. In March 2014, due to a large particle contamination incident at the empagliflozin production plant in Boehringer, the application of new drug submitted by the Boehringer-Eli Lilly Alliance was rejected by FDA. In June 2014, after reviewing the summary and material submitted by Boehring in March, confirming that the quality management and compliance system of the Boehring drug production facility was acceptable, FDA withdrew the previously issued warning letter. The Boehringer-Eli Lilly Alliance also filed an application with the FDA on June 17th.

864070-44-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name empagliflozin

1.2 Other means of identification

Product number -
Other names X5927

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:864070-44-0 SDS

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields